Skip to main content

Table 1 Patient characteristics thought to be potentially relevant to GC prescribing practices

From: Half of UK patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study

Patient demographics Age
Gender
GC-associated comorbidities Musculoskeletal Osteoporosis, avascular necrosis, myopathy
Endocrine/metabolic Diabetes
Cardiovascular Hypertension, hyperlipidaemia, cardiovascular diseases (myocardial infarction, angina, stroke)
Gastrointestinal Peptic ulcer disease, pancreatitis
Psychological/behavioural Depression, psychosis, insomnia
Inflammatory comorbidities Respiratory Chronic obstructive pulmonary disease, asthma, lower respiratory tract infections
Skin diseases Atopic eczema, cutaneous vasculitis, cutaneous lupus
Gastrointestinal diseases Inflammatory bowel disease (ulcerative colitis, Crohn’s disease)
DMARDs Methotrexate  
Sulfasalazine  
Hydroxychloroquine  
Leflunomide  
Other DMARDs Cyclosporine, azathioprine, penicillamine, chloroquine, gold
  1. GC glucocorticoid, DMARDs disease-modifying anti-rheumatic drugs